EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Empagliflozin in HNF1A-MODY (MODY3): A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial

Henrik Maagensen iD, Stine O Høyerup, Johanne S Jensen, Anne C B Thuesen, Julie L Forman, Henrik H Thomsen, Henrik Vestergaard, Filip K Knop, Torben Hansen, Sofie Hædersdal, Julie Støy, Tina Vilsbøll iD

Diabetes Care · 01.07.2026 · 49 (7) · 1166-1174

DOI: 10.2337/dc25-2572 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes Care, online erschienen am 12.01.2026. Verfasst von Henrik Maagensen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Copenhagen University Hospital - Steno Diabetes Center Copenhagen, Herlev, Denmark. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Glucosides, Diabetes Mellitus, Type 2, Hypoglycemic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Dexcom, Novo Nordisk Fonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE Maturity-onset diabetes of the young (MODY) caused by pathogenic variants in HNF1A is a common form of monogenic diabetes. Sulfonylurea drugs are considered first-line treatment of HNF1A-MODY (MODY3), but intensified treatment is often needed. HNF1A encodes a transcription factor involved in the regulation of the sodium–glucose cotransporter 2 (SGLT2). Accordingly, the glucose-lowering efficacy of SGLT2 inhibitors in HNF1A-MODY is questionable. Here, we assess the glucose-lowering effect of the SGLT2 inhibitor empagliflozin as an add-on for treatment of individuals with HNF1A-MODY. RESEARCH DESIGN AND METHODS MOD3ST-TRIAL was a randomized, double-blind, placebo-controlled crossover trial. Adults with HNF1A-MODY treated with at least one glucose-lowering drug were randomized to be treated with empagliflozin 25 mg for 4 weeks followed by a 2-week washout period and then received placebo for 4 weeks or the opposite sequence. The primary outcome was mean glucose concentration assessed by 10 days of continuous glucose monitoring (CGM). RESULTS Nineteen individuals were randomized and 18 participants (n = 10 women [56%]; median [Q1, Q3] HbA1c 7.5% [7.0, 8.4] or 58 [53, 68] mmol/mol, mean [SD] CGM glucose concentration 10.4 [2.5] mmol/L) completed the study. Compared with placebo, empagliflozin lowered the mean glucose level 2.3 mmol/L (95% CI 1.3 to 3.3; P = 0.0001). There were no significant differences in hypoglycemic outcomes. Adverse events were generally mild and transient, and no severe adverse events or study drug discontinuations were attributable to empagliflozin. CONCLUSIONS Empagliflozin used for 4 weeks in adjunction with other glucose-lowering treatments markedly improved glycemia compared with placebo in individuals with HNF1A-MODY without significantly increasing risk of hypoglycemia or unexpected adverse effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Benzhydryl CompoundsGlucosidesDiabetes Mellitus, Type 2Hypoglycemic AgentsHumansDouble-Blind MethodCross-Over StudiesHepatocyte Nuclear Factor 1-alphaFemaleAdultMaleBlood GlucoseSodium-Glucose Transporter 2 InhibitorsMiddle Aged

Substanzen

Benzhydryl CompoundsempagliflozinGlucosidesHepatocyte Nuclear Factor 1-alphaHypoglycemic AgentsBlood GlucoseHNF1A protein, humanSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Copenhagen University Hospital - Steno Diabetes Center Copenhagen, Herlev, Denmark.
  • Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Section of Biostatistics, Department of Public Health, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Medical Diagnostic Center, University Clinic for Innovative Patient Pathways, Regional Hospital Central Jutland, Viborg, Denmark.
  • Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
  • Center for Clinical Metabolic Research, Copenhagen University Hospital - Herlev and Gentofte, Hellerup, Denmark.

ORCID-Profile: Henrik Maagensen, Tina Vilsbøll

Förderung

  • Dexcom
  • Novo Nordisk Fonden

Zitieren

APA

Maagensen, H., Høyerup, S. O., Jensen, J. S., Thuesen, A. C. B., Forman, J. L., Thomsen, H. H., Vestergaard, H., Knop, F. K., Hansen, T., Hædersdal, S., Støy, J., & Vilsbøll, T. (2026). Empagliflozin in HNF1A-MODY (MODY3): A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial. Diabetes Care, 49(7), 1166-1174. https://doi.org/10.2337/dc25-2572

Vancouver

Maagensen H, Høyerup SO, Jensen JS, Thuesen ACB, Forman JL, Thomsen HH, et al. Empagliflozin in HNF1A-MODY (MODY3): A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial. Diabetes Care. 2026;49(7):1166-1174. doi:10.2337/dc25-2572

BibTeX
@article{Maagensen2026,
  author = {Maagensen, Henrik and Høyerup, Stine O and Jensen, Johanne S and Thuesen, Anne C B and Forman, Julie L and Thomsen, Henrik H and Vestergaard, Henrik and Knop, Filip K and Hansen, Torben and Hædersdal, Sofie and Støy, Julie and Vilsbøll, Tina},
  title = {Empagliflozin in HNF1A-MODY (MODY3): A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial},
  journal = {Diabetes Care},
  year = {2026},
  volume = {49},
  number = {7},
  pages = {1166--1174},
  doi = {10.2337/dc25-2572}
}
Kostenlos starten →